论文部分内容阅读
现已证明,原发性血小板增多症(下称 ET)为累及多能造血干细胞的克隆性疾病,与真红(PV)、慢粒(CML)及骨髓纤维化(MF)同属骨髓增生性疾病(MPD),其特点是以血小板增高为主伴有粒系和红系成熟细胞增生。最近真红研究组(PVSG)报导了对151例 ET 病人的诊断与治疗研究的中期结果。ET 的诊断:ET 与其他骨髓增生性疾病有许多相似之处,故在某些病例常遇到诊断困难。PVSG 于1970年提出的 ET 诊断标准如下:Ⅰ、血小板>60万
It has been demonstrated that essential thrombocythemia (ET) is a clonal disease involving pluripotent hematopoietic stem cells and is associated with myeloproliferative disorders such as true red (PV), chronic myeloma (CML) and myelofibrosis (MF) (MPD), which is characterized by thrombocytopenia accompanied by granulocyte and erythroid mature cell hyperplasia. The recent True Red Research Group (PVSG) reported the interim results of a study of 151 patients with ET in the diagnosis and treatment. ET diagnosis: ET and many other myeloproliferative diseases have many similarities, so in some cases often encounter diagnostic difficulties. PVSG in 1970 proposed ET diagnostic criteria are as follows: Ⅰ, platelets> 600,000